262 filings
Page 5 of 14
8-K
7bvj83 a0pgkzkryg
10 Mar 21
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD
7:03am
8-K
e0hluav t9eo92n
23 Feb 21
Results of Operations and Financial Condition
4:08pm
8-K
6cbz9nk0pr7wpoed5
16 Feb 21
Other Events
7:05am
8-K
3cqbkcks
9 Feb 21
Departure of Directors or Certain Officers
4:12pm
8-K
z2xfaosi1 yita
11 Jan 21
Results of Operations and Financial Condition
8:05am
8-K
r5tbjo3prq3ip58
18 Dec 20
Amendments to Articles of Incorporation or Bylaws
8:47am
8-K
l7d ht30k
7 Dec 20
No severe vaso-occlusive events (VOEs) reported through 24 months of follow-up in Group C patients
4:35pm
8-K
i9176hnznnaeqvfc 2sz
7 Dec 20
Bristol Myers Squibb and bluebird bio Present Data Highlighting
8:01am
8-K
44hwcgu
4 Dec 20
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to
8:15am
8-K
vufalx
4 Nov 20
Results of Operations and Financial Condition
4:08pm
8-K
9n7yr32ih88uqam
2 Oct 20
Other Events
6:06am
8-K
i914m4 746tx0y
1 Oct 20
Departure of Directors or Certain Officers
7:00am
8-K
sh45yg ss1sd
23 Sep 20
EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need
7:01am
8-K
8sj8efoadpk
22 Sep 20
Other Events
7:53am
8-K
zuoe9
31 Aug 20
Other Events
6:29am
8-K
8tv6wkeg3iaumvpvsyi
18 Aug 20
Departure of Directors or Certain Officers
4:23pm
8-K
czs nx06m947
11 Aug 20
Departure of Directors or Certain Officers
7:21am
8-K
fg90 4jihh
5 Aug 20
Other Events
4:14pm
8-K
hqga5jle
29 Jul 20
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License
4:41pm
8-K
4bn6asys eoxq
23 Jun 20
Submission of Matters to a Vote of Security Holders
4:02pm